Rising cases of psoriasis along with the unavailability of precise therapies are anticipated to propel the demand for advanced drugs and therapeutic techniques. Such innovative techniques are likely to increase the efficacy and safety while curing the disease. In addition, better drugs and therapies can support controlling the spread of the disease.
Interlukin Inhibitors to Witness the Fastest Growth
Major therapeutic classes for psoriasis are interleukin inhibitors, Tumor Necrosis Factor (TNF), and vitamin D analogues. In the coming years, interleukin inhibitors are anticipated to witness the maximum growth owing to improved efficacy and safety profiles. Some of the well-known interleukin inhibitors include Taltz (ixekizumab), Siliq (brodalumab), Stelara (ustekinumab), Cosentyx (secukinumab), and Tremfya (guselkumab). On the other hand, the TNF inhibitors segment may witness a decline on account of growing adoption of IL-inhibitor drugs.
Most of the prominent companies in the field are focusing on R&D activities to introduce safer, more effective drugs for the disease treatment. For instance, a team of researchers from the University of Geneva (UNIGE) and Geneva University Hospitals recently tested a molecular inhibitor of interlukin-18 or IL-18 successfully. The encouraging results of this test, in terms of efficacy and safety, are likely to offer a new way of treatment for psoriasis, as well as several other inflammatory diseases.
Market Insights
The global psoriasis drugs market is likely to reach at USD 21.4 billion by 2022 growing at a CAGR of 9.3 % during the forecast period (from 2016 to 2022), according to a report by Grand View Research, Inc. Increasing number psoriasis patients across the globe is anticipated to be the major factor during the market demand. In addition, increasing awareness regarding the disease among people is expected to spur the market expansion.
Growing number of reimbursement guidelines for the disease treatment would also fuel the market demand in near future. availability of advanced therapeutic techniques owing to constant technological developments can further drive the market growth in the coming years. Some of the leading companies offering effective therapeutics for psoriasis are AbbVie Inc.; Novartis AG; Amgen Inc.; Eli Lilly & Company; Johnson & Johnson; and AstraZeneca.
Read more: https://www.grandviewresearch.com/industry-analysis/psoriasis-drugs-market
Read more: https://www.grandviewresearch.com/industry-analysis/psoriasis-drugs-market
No comments:
Post a Comment